<DOC>
	<DOC>NCT02263924</DOC>
	<brief_summary>Phase III, single-centre, double-blind, randomised, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of oral Vitamin E (Mixed Tocotrienol) for 6 months in patients with moderate ischemic stroke. 150 patients will be recruited. Half will receive mixed tocotrienol 200mg twice a day for 6 months while the other half will receive placebo capsules.</brief_summary>
	<brief_title>Stroke and Tocotrienol: Unique Role in Neuroprotection</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<criteria>Age 35 years old and above Subject will be included within the time frame of 110 days after the first onset of acute cerebral ischemic stroke with NIHSS 620 Subject is neurologically stable after stroke onset, i.e. no fluctuation in clinical conditions. Subject has a Modified Rankin Scale from 24 Subject has a clinical stroke diagnosis according to WHO stroke diagnosis Subject is willing to attend at least four sessions of physiotherapy during the study or as deemed needed by the physiotherapist Subject or his/her legally accepted representatives is willing to provide written informed consent Subject has evidence of intracerebral hemorrhage on brain CT scan or MRI Severe stroke as assessed clinically and/or by appropriate imaging techniques Subject has other significant nonischemic brain lesion(s) which could affect function or disability Time of ischemic stroke onset not exactly known Subject has coexisting systemic disease which may affect assessment or followup such as terminal cancer, renal failure (serum creatinine &gt;200umol/L if known), liver cirrhosis, severe dementia or psychosis, connective tissue disease, rheumatoid arthritis Subject with significant liver impairment (liver function tests of five time the upper limit level) Subject has definite indications for full dose or longterm anticoagulation therapy (such as warfarin) Any condition that in the judgement of the investigator would place the patient under undue risks Traumatic brain injury within the previous 30days Symptoms which are rapidly improving (as in transient ischemic stroke) Patient with recurrent stroke The patient is female with childbearing potential (unless the subjects are on contraception measurement) or breast feeding Patients who have been included in any other clinical trials within the previous three months</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>